Revolution Medicines

Revolution Medicines is a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers.  Its mission is to revolutionize the treatment for these patients through the discovery, development, and delivery of innovative, innovative medicines.

The team at Revolution Medicines consider themselves ‘Revolutionaries’ – passionate in their mission to help those living with RAS-addicted cancers, which include pancreatic, lung, and colorectal cancers.  The team believes in challenging the status quo to find new therapeutic approaches to some of the toughest cancers, and that we, as a society, have the potential to change the treatment paradigm in cancers where there is a significant unmet medical need.

Founded in 2015, Revolution Medicines recognizes that every minute counts in the fight against RAS-addicted cancers; the team focuses on the toughest cancer targets, applying an innovative, curious, and rigorous approach to research and development in their pursuit of novel therapeutic breakthroughs.

In late 2020, the JIMCO Life Sciences fund became an investor in biomedical start-up, EQRx and further increased our commitment in 2021; in November 2023, EQRx was acquired by Revolution Medicines.